VINC: Vincerx Pharma, Inc. Stock

by  •  • Comments Off on VINC: Vincerx Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 0.52
Enterprise Value ($M) -3.91
Book Value ($M) 2.07
Book Value / Share 0.39
Price / Book 0.25
NCAV ($M) 2.07
NCAV / Share 0.39
Price / NCAV 0.25

Profitability (mra)
Return on Invested Capital (ROIC) -10.96
Return on Assets (ROA) -2.04
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 1.79
Current Ratio 1.79

Balance Sheet (mrq) ($M)
Current Assets 4.69
Assets 4.69
Liabilities 2.62
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -29.06
Net Income -30.07
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -26.13
Cash from Investing 0.21
Cash from Financing 17.99

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-15 13G/A Armistice Capital, Llc 4.99
02-12 13G/A Prosight Management, LP 4.99
02-11 13G/A Long Focus Capital Management, Llc 0.00 -100.00
11-14 13G/A Bank Of America Corp /de/ 0.00 -99.98

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPOR
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PUR
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT

(click for more detail)

Similar Companies
VETOF – Vetoquinol SA VGLS – VG Life Sciences Inc.
VICP – Vicapsys Life Sciences, Inc. VIRX – Viracta Therapeutics, Inc.
VREOF – Vireo Growth Inc.


Financial data and stock pages provided by
Fintel.io